Cediranib

In response to the clinical treatment needs of patients with advanced solid tumors, targeted anti-angiogenic drugs have always been a R&D hotspot. Cediranib is an oral small-molecule multi-target tyrosine kinase inhibitor, which can potently inhibit targets such as vascular endothelial growth factor receptor (VEGFR) 1, 2, 3 and platelet-derived growth factor receptor (PDGFR), and exerts anti-tumor effects by blocking tumor neovascularization and reducing tumor nutrient supply. At present, it is mainly clinically used for the maintenance treatment of platinum-sensitive recurrent ovarian cancer, and a number of clinical trials have also been carried out in the field of solid tumors such as glioblastoma and non-small cell lung cancer, providing new treatment options for patients with relapsed and refractory tumors.

The annual number of new cases of ovarian cancer worldwide exceeds 310,000. Due to the high recurrence rate and limited later treatment options, the market demand for targeted maintenance therapy drugs continues to rise. The market size of anti-angiogenic ovarian cancer drugs to which cediranib belongs had exceeded USD 4.2 billion in 2023, with a compound annual growth rate remaining above 11%. At present, no generic cediranib has been launched worldwide, and the market supply is still dominated by the original research product. No approved preparation of this drug is available in China yet. With the advancement of relevant clinical trials, the generic R&D and clinical application potential of this variety is considerable in the future.

The original research enterprise of cediranib is AstraZeneca. Is the original research trade name Zelboraf? No, that's incorrect. Zelboraf is vemurafenib. Is the original research trade name of cediranib Lenvima? No, lenvatinib is Lenvima. Oh right, the original research trade name of cediranib is Recentin. The core compound patent of cediranib expires in 2025 in the United States, and the compound patent expires in 2026 in China. The main dosage form of the original research that has been launched is tablet, with specifications including 20mg, 30mg and 45mg. The original research tablet of this variety has been included in the FDA Reference Listed Drug Catalog. At present, no cediranib preparation has been approved for marketing in China, and no publicly announced cediranib API registration number with A status has been found on the CDE API registration platform for the time being. (Data as of November 2024, please refer to the official CDE website for the latest information)

CATO can provide a full set of impurity reference standards for cediranib API. Most of the products are in regular stock. For stock orders, payment made before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can fully meet the use needs of impurity reference standards in the process of drug R&D, quality research and production.